Roche will showcase a science-driven and patient-centric exhibit at the 2023 American Association of Clinical Chemistry (AACC) Scientific Meeting and Clinical Lab Expo, July 23-27 in Anaheim, California.
Roche will feature its newest innovations including the cobas 5800, a compact, fully-automated molecular PCR-testing solution with a comprehensive menu of assays, and cobas pure integrated solutions, which combine clinical chemistry, immunoassay and Ion-Selective Electrode (ISE) diagnostic testing on a single platform for low- to mid-volume testing needs. The new cobas connection modules (CCM vertical), a flexible modular system that uses lab space effectively and seamlessly integrates into the existing cobas connection modules, will also be highlighted, along with Roche’s vision for the transformation of mass spectrometry testing. The cobas pulse system, a next generation point-of-care blood glucose management device and digital platform, will also be available for attendees to experience. Finally, Roche will introduce its navify digital solutions, an end-to-end integrated, secure and cohesive solution that delivers data-driven insights to enhance efficiency across the healthcare ecosystem.
Roche will also present seven Roche Idea Lab segments in booth 2201, where experts will discuss topics such as mass spectrometry, digital solutions, point of care, and the use of high-medical-value assays when treating Alzheimer’s disease and heart failure. Scientific industry workshops will include “The future of mass spectrometry from Roche,” “The future of diagnostics in the evolving Alzheimer’s disease care landscape” and “Precision medicine from a pathologist’s perspective in China.” For more information about Roche’s participation at AACC 2023 and Roche Idea Lab programming, visit AACC.roche.com.
